Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs

被引:35
作者
Chen, C
Casale, EJ
Duncan, B
Calverhouse, EH
Gilman, J
机构
[1] Glaxo Wellcome Inc, Div Clin Pharmacol, Res Triangle Pk, NC 27709 USA
[2] Glaxo Wellcome Inc, Div Cent Nervous Syst Clin Res, Res Triangle Pk, NC 27709 USA
[3] Glaxo Wellcome Inc, Div Clin Pharmacol Data Sci, Res Triangle Pk, NC 27709 USA
[4] Glaxo Wellcome Inc, Div Bioanal & Drug Metab, Res Triangle Pk, NC 27709 USA
[5] Miami Childrens Hosp, Dept Neurosci, Miami, FL USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 04期
关键词
D O I
10.1592/phco.19.6.437.31052
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We evaluated the pharmacokinetics of lamotrigine in 12 children with epilepsy who were receiving no other antiepileptic drugs. Each patient received a single oral dose of lamotrigine 2 mg/kg. Plasma concentrations of the drug were measured up to 48 hours after dosing. Pharmacokinetic parameters were calculated using concompartmental methods. After rapid absorption, the lamotrigine concentration declined monoexponentially. Oral clearance was 0.64 +/- 0.26 ml/min/kg. The apparent volume of distribution was 1.50 +/- 0.51 L/kg. Weight-normalized clearance and volume were higher in children than in adults. The mean half-life was 32 hours, similar to that in adults. Should similar plasma lamotrigine: concentrations in adults and children be desirable, children will likely require higher weight-normalized doses at the same dosing frequency.
引用
收藏
页码:437 / 441
页数:5
相关论文
共 33 条
[21]   A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy [J].
Reunanen, M ;
Dam, M ;
Yuen, AWC .
EPILEPSY RESEARCH, 1996, 23 (02) :149-155
[22]  
ROWE PC, 1987, H LANE HDB
[23]   IMMUNOFLUOROMETRIC ASSAY FOR LAMOTRIGINE (LAMICTAL) IN HUMAN PLASMA [J].
SAILSTAD, JM ;
FINDLAY, JWA .
THERAPEUTIC DRUG MONITORING, 1991, 13 (05) :433-442
[24]   LAMOTRIGINE - A 6-MONTH, PLACEBO-CONTROLLED, SAFETY AND TOLERANCE STUDY [J].
SCHACHTER, SC ;
LEPPIK, IE ;
MATSUO, F ;
MESSENHEIMER, J ;
FAUGHT, E ;
MOORE, EL ;
RISNER, ME .
JOURNAL OF EPILEPSY, 1995, 8 (03) :201-209
[25]   DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF LAMOTRIGINE IN TREATMENT-RESISTANT PARTIAL SEIZURES [J].
SCHAPEL, GJ ;
BERAN, RG ;
VAJDA, FJE ;
BERKOVIC, SF ;
MASHFORD, ML ;
DUNAGAN, FM ;
YUEN, WC ;
DAVIES, G .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (05) :448-453
[26]  
*SCI CONS INC, 1995, WINNONLIN US GUID
[27]   OUTCOMES OF ADD-ON TREATMENT WITH LAMOTRIGINE IN PARTIAL EPILEPSY [J].
SMITH, D ;
BAKER, G ;
DAVIES, G ;
DEWEY, M ;
CHADWICK, DW .
EPILEPSIA, 1993, 34 (02) :312-322
[28]  
Steiner TJ, 1994, EPILIPSIA, V35, P61
[29]  
Tharp B R, 1987, Epilepsia, V28 Suppl 1, pS36, DOI 10.1111/j.1528-1157.1987.tb05755.x
[30]  
Trevathan Edwin, 1996, Epilepsia, V37, P202